Latest Breaking News On - Patients with unresectable or metastatic urothelial carcinoma - Page 1 : comparemela.com

The European Medicines Agency has validated a type II variation application for the first-line combination of nivolumab and cisplatin-based chemotherapy for adult patients with unresectable or metastatic urothelial carcinoma.

Dana walkerGlobal health statusEuropean unionBristol myers squibbEuropean medicines agencyNew england journalHealth statusMedicines agencyBristol myersNivolumab and cisplatin based chemotherapyPatients with unresectable or metastatic urothelial carcinoma